Literature DB >> 31486857

[Use of monoclonal antibodies in pathological diagnostics].

S Förster1, A Tannapfel2.   

Abstract

In pathological diagnostics, monoclonal antibodies (mAb) are mainly used for immunhistochemical analysis. After an initial histological evaluation, a precise panel of antibodies is selected in order to stain the slides by using an indirect immune method. The most frequent issues include localisation of the primary tumor in cases of metastases, determination of undifferentiated tumors, subtyping of lympho-proliferative diseases and soft tissue tumors, as well as the assessment of proliferation via Ki-67. Increasing importance in mAb-based diagnostics is attributed to the analysis of predictive biomarkers such as hormone receptors, mismatch repair proteins (MMR) and programmed death ligand 1 (PD-L1). Their evaluation is performed by using different scores, which the clinical physician needs to be aware of due to their direct therapeutic implications.

Entities:  

Keywords:  Biomarkers; DNA mismatch repair proteins; Immunohistochemistry; Ki-67 antigen; PD-L1 protein, human

Mesh:

Substances:

Year:  2019        PMID: 31486857     DOI: 10.1007/s00108-019-00667-1

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  17 in total

Review 1.  The Ki-67 protein: from the known and the unknown.

Authors:  T Scholzen; J Gerdes
Journal:  J Cell Physiol       Date:  2000-03       Impact factor: 6.384

Review 2.  [Role of cytology in hematopathological diagnostics].

Authors:  B Bode; M Tinguely
Journal:  Pathologe       Date:  2012-07       Impact factor: 1.011

3.  Immunohistochemical distinction between merkel cell carcinoma and small cell carcinoma of the lung.

Authors:  Mattheos Bobos; Prodromos Hytiroglou; Ioannis Kostopoulos; Georgios Karkavelas; Constantine S Papadimitriou
Journal:  Am J Dermatopathol       Date:  2006-04       Impact factor: 1.533

Review 4.  Challenges in the interpretation of peritoneal cytologic specimens.

Authors:  Oscar Lin
Journal:  Arch Pathol Lab Med       Date:  2009-05       Impact factor: 5.534

Review 5.  [Chances and risks of blood-based molecular pathological analysis of circulating tumor cells (CTC) and cell-free DNA (cfDNA) in personalized cancer therapy: positional paper from the study group on liquid biopsy of the working group for molecular pathology in the German Society of Pathology (DGP)].

Authors:  E Dahl; A Jung; J Fassunke; M Hummel; R Penzel; W Dietmaier; S Laßmann
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

6.  HER2 testing in gastric cancer: a practical approach.

Authors:  Josef Rüschoff; Wedad Hanna; Michael Bilous; Manfred Hofmann; Robert Y Osamura; Frédérique Penault-Llorca; Marc van de Vijver; Giuseppe Viale
Journal:  Mod Pathol       Date:  2012-01-06       Impact factor: 7.842

Review 7.  Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma.

Authors:  T Tot
Journal:  Eur J Cancer       Date:  2002-04       Impact factor: 9.162

8.  Mismatch repair protein expression in colorectal cancer.

Authors:  Elrasheid A H Kheirelseid; Nicola Miller; Kah Hoong Chang; Catherine Curran; Emer Hennessey; Margaret Sheehan; Michael J Kerin
Journal:  J Gastrointest Oncol       Date:  2013-12

9.  Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases.

Authors:  Anja M Schmitt; Florian Riniker; Martin Anlauf; Sonja Schmid; Alex Soltermann; Holger Moch; Philipp U Heitz; Günther Klöppel; Paul Komminoth; Aurel Perren
Journal:  Am J Surg Pathol       Date:  2008-03       Impact factor: 6.394

10.  A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors.

Authors:  Jyothi S Prabhu; Aruna Korlimarla; Krisha Desai; Annie Alexander; Rohini Raghavan; Ce Anupama; Nandini Dendukuri; Suraj Manjunath; Marjorrie Correa; N Raman; Anjali Kalamdani; Msn Prasad; K S Gopinath; B S Srinath; T S Sridhar
Journal:  J Cancer       Date:  2014-01-23       Impact factor: 4.207

View more
  1 in total

1.  Deep learning for the standardized classification of Ki-67 in vulva carcinoma: A feasibility study.

Authors:  Matthias Choschzick; Mariam Alyahiaoui; Alexander Ciritsis; Cristina Rossi; André Gut; Patryk Hejduk; Andreas Boss
Journal:  Heliyon       Date:  2021-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.